ABOUT US

About Northway Biotech EU

Northway Biotech is a flexible biologics CDMO headquartered in the EU member state of Lithuania, a fast-growing biotech hub with a state-subsidized university system that supports a highly-educated scientific workforce.

Our global teams based in the US and Europe are exceptionally well-versed in all aspects of the biopharmaceutical value chain, from cell line development to commercial production and aseptic fill-finish. We continually invest in expansion at our modern facilities, located just 20 minutes from Vilnius Airport, which makes us easily accessible via multiple daily flights from many European hubs. We are deeply invested in providing high quality, world-class CDMO services and long-term partnerships based on our blend of experience and openly collaborative project teams.

Management & Advisory Board

Prof. Vladas Algirdas Bumelis

CEO, Executive Chairman of the Board & Advisory Board

Prof. Vladas Bumelis is the Founder of Northway Biotech and currently serves as Chairman of the company’s Board and Advisory Board. With extensive experience in the pharmaceutical and biotech industries, he previously held key positions such as General Manager of Sicor Biotech UAB (now Teva Pharmaceutical Industries Ltd.), Chairman of the Board for Biofa and Biotechna, and served as Chairman of the Board and General Manager of the Institute of Applied Enzymology in Lithuania.

Prof. Bumelis is the author of 157 scientific publications and 32 inventions. Notable accolades include being named CEO of the year in Lithuania in 2012 and receiving the Lithuanian Science Prize in 2004 for his pioneering work in the development and production of recombinant proteins. In 2020, he was honored with the Officer's Cross Award of the Order "For Merit to Lithuania."

Prof. Bumelis holds a Ph.D. and MSc in Chemistry, along with a Ph.D. in Biotechnology from Vilnius University.

Diana Bumelytė

Member of the Board

Diana has over 20 years of experience in running medical centers and working as a general practitioner. She worked at Seskines Healthcare in Vilnius before setting up Northway Medicinos Centrai ("Northway" is one of the largest private medical centers in Lithuania providing comprehensive medical services in Lithuania, Latvia and London, UK), where she has been General Manager for the last 15 years. Diana has a medical degree from Vilnius University.

Eugenija Sutkienė

Member of the Board

Eugenija is a leading expert in pharmaceutical, life sciences, mergers and acquisitions, and commercial law.
She has over 25 years of legal services experience acting as a legal advisor to corporations such as Coca-Cola, Mars Inc., Philip Morris, Sicor Biotech UAB, Svenska Petroleum as well as an advisor to the Lithuanian Government. She studied at Vilnius University where she graduated as Master of Law, she also studied International Law at Krakow University.
Eugenija has been recognised as being in the top 4 most influential women in Lithuania, Valstybe (The State), and by the IFLR1000 which recognises the top 300 female lawyers considered to be among the best transactional specialists in their markets and practice areas.

Advisory Board

Harold Paisner (London)
Gianni Morosoli (Switzerland)
Marvin Samson (USA)
Michael D. Cannon (USA)

Operations Team

Business Development Team

André Markmann, Ph.D.

Vice President, Business Development

André holds a Ph.D. in biochemistry and has more than 20+ years of experience in the biopharmaceutical industry, having worked for global companies like Sanofi-Aventis and DSM/Patheon. For more than 18 years, André has specialized in Business Development for CDMOs with a focus on process development and cGMP manufacturing of biologicals.

John Sandles

Director, Business Development

John has more than 12 years experience in the biopharmaceutical manufacturing industry working in technical, strategy and commercial roles. He holds a MBA where he focused on life sciences and partnered with biotechs for consultancy projects. John also authored a report which was included in the UK Government‘s Life Science Industrial Strategy.